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mBackground:Multiple primary melanoma (MPM), in concert with a positive family history, is a predictor of
cyclin-dependent kinase (CDK) inhibitor 2A (CDKN2A) germline mutations. A rule regarding the presence
of either 2 or 3 or more cancer events (melanoma and pancreatic cancer) in low or high melanoma
incidence populations, respectively, has been established to select patients for genetic referral.Objective: We sought to determine the CDKN2A/CDK4/microphthalmia-associated transcription factor
mutation rate among Italian patients with MPM to appropriately direct genetic counseling regardless of
family history.Methods: In all, 587 patients with MPM and an equal number with single primary melanomas and control
subjects were consecutively enrolled at the participating centers and tested for CDKN2A, CDK4, and
microphthalmia-associated transcription factor.Results: CDKN2A germline mutations were found in 19% of patients with MPM versus 4.4% of patients with
single primary melanoma. In familial MPM cases the mutation rate varied from 36.6% to 58.8%, whereas inthe Departments of Internal Medicinea and Medical Spe-
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326 Bruno et alsporadic MPM cases it varied from 8.2% to 17.6% in patients with 2 and 3 or more melanomas, respectively.
The microphthalmia-associated transcription factor E318K mutation accounted for 3% of MPM cases
altogether.Limitations: The study was hospital based, not population based. Rare novel susceptibility genes were not
tested.Conclusion: Italian patients who developed 2 melanomas, even in situ, should be referred for genetic
counseling even in the absence of family history. ( J Am Acad Dermatol 2016;74:325-32.)
Key words: cyclin-dependent kinase; cyclin-dependent kinase inhibitor 2A; family history; genetic
assessment; melanoma; microphthalmia-associated transcription factor; mutation; pancreatic cancer.CAPSULE SUMMARY
d Cyclin-dependent kinase inhibitor 2A is
the main candidate gene for germline
testing in families with melanoma and
patients with multiple primary
melanoma. In Italy, mutation prevalence
is influenced by founders.
d Despite regional differences, the Italian
cyclin-dependent kinase inhibitor 2A
mutation rate is about 10% even in
patients with multiple primary
melanoma and only 2 melanomas,
including in situ melanomas.
d Patients with multiple primary
melanoma from Italy warrant genetic
testing regardless of family history.Cutaneous melanoma
incidence is on the rise
in Caucasian populations.1-3
The etiology of cutaneous
melanoma involves host
characteristics and environ-
mental risk factors, however
the main risk factor is a
positive family history.4,5
Germline mutations in
cyclin-dependent kinase
(CDK) inhibitor 2A
(CDKN2A) (INK4a) are
reported in 5% to 40% of
hereditary cases, thus mak-
ing it the most significant
high-risk melanoma suscep-
tibility gene. Mutations in
CDK4 are rare.6-11 The differ-
ences in the incidence of
melanoma and penetrance
of CDKN2A mutations among countries are such
that there is no single guideline for genetic testing
that could be applied worldwide.12,13 Leachman
et al13 proposed that 2 cancer events, including
pancreatic cancer, either in the patient or in a family
member, are criteria enough to best identify which
patients would benefit from genetic testing in low
melanoma incidence areas. Italy was included
among these areas on the basis of mutation preva-
lence data from the Ligurian population12,14-18 where
CDKN2A founder mutations were prevalent in up to
40% of melanoma families in concert with a strong
association with pancreatic cancer.19,20 The Italian
study based on the Italian Society of HumanGenetics
(SIGU) protocol for melanoma families found that
33% of the families overall and 25% of those with
only 2 affected members carried CDKN2A
mutations.21,22 An increase in the frequency of
mutations was observed in patients whose family
members had multiple primary melanomas (MPM).
A Ligurian hospital-based study of single primary
melanoma (SPM) and MPM found that the frequencyof CDKN2A mutations in
MPM cases was 32.6%,
and that from 8% to 15% of
patients with MPM without a
family history of cutaneous
melanoma harbored a
CDKN2A mutation.23
Estimates of the prevalence
of CDKN2A mutations for re-
gions with different
melanoma incidence
(United Kingdom, Australia,
Spain) showed a low proba-
bility of detecting a CDKN2A
mutation in people with mel-
anoma except for those with
a family history of melanoma
(2 affected relatives, 25%), 3
or more primary melanomas
(29%), or more than 1
primary melanoma who alsohave other affected relatives (27%).24 In France,
another low melanoma incidence country, the fre-
quency of CDKN2A mutations in families with 2
patients with melanoma was 13%, but this percent-
age increased to 22% when the median age at
diagnosis was younger than 50 years and to 29%
when there was 1 or more subjects with MPM.25,26
Recently, a melanoma predisposing mutation was
identified in microphthalmia-associated transcrip-
tion factor (MITF ) E318K, and a Ligurian study
supportedMITF as a medium-penetrance melanoma
susceptibility gene.27-30 Novel melanoma suscepti-
bility genes have also been identified, but their
geographic prevalence and penetrance has yet to
be established.31-36 The aim of our study was to carry
out a nationwide evaluation of the mutation rate of
melanoma susceptibility genes CDKN2A, CDK4, and
MITF and associated features in patients with MPM to
establish whether, even in the absence of family
history, MPM may be added as a criterion to update
the national recommendations for genetic testing for
hereditary melanoma.
Abbreviations used:
CDK: cyclin-dependent kinase
CDKN2A: cyclin-dependent kinase inhibitor 2A
MITF: microphthalmia-associated transcrip-
tion factor
MPM: multiple primary melanoma
SIGU: Italian Society of Human Genetics
SPM: single primary melanoma
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Case selection
The multiMEL study was performed on 587
patients with MPM and SPM consecutively enrolled
during their follow-up between 2010 and 2012 and
on control subjects (ie, friends, spouses, colleagues,
blood donors), to evaluate genetic variants that had
not previously been described, for a total of 1749
samples. The participating Italian Melanoma
Intergroup centers included: Genoa (University of
Genoa and IRCCS AOU San MartinoeIST), Padua
(Veneto Institute of Oncology, IOV/University of
Padua), Milan (Fondazione IRCCS Istituto
Nazionale Tumori and European Institute of
Oncology), Bergamo (Ospedale Papa Giovanni
XXIII), Florence (University of Florence and Santa
Maria Annunziata Hospital), Turin (University of
Turin and Gradenigo Hospital), Naples (Pascale
Foundation), Sassari (National Research Council),
and Varese (Ospedale di Circolo-University of
Insubria). Only patients with SPM who had been
given a diagnosis at least 3 years before the begin-
ning of our study were recruited because of the
increased risk of a second melanoma during the
2 years after the diagnosis.37,38 The number of
melanomas, age at diagnosis, diagnostic patholog-
ical data, cancer family history, and phenotyping
were recorded for each patient through a standard-
ized questionnaire. Confirmation was requested for
reported diagnoses of pancreatic cancer in the
family, at least by medical records when death
certificates or pathology reports were not available,
and obtained for about 50% of pancreatic cancer
cases. Each participating center recruited at least 20
patients with MPM, 20 patients with SPM, and a
corresponding number of control subjects. The study
was approved by the local ethics committees of all
participating centers. Written informed consent was
obtained from all participants.
Molecular analyses
The same standard protocol was followed at all
the centers that performed molecular analyses.
Samples from the European Institute of Oncology
and from the centers of Turin, Varese, and Bergamowere sent to Genoa, whereas samples from the
remaining centers were tested locally. Of the 282
samples tested by other laboratories, 10% were
selected randomly by the coordinating center of
Genoa and blindly analyzed. No discrepancies were
detected. CDKN2A, along with CDK4 exon 2 and
MITF exon 10, were analyzed on genomic DNA
extracted from peripheral blood.14,15,22,29,39-41
Multiplex ligation-dependent probe amplification
was performed to exclude CDKN2A large deletions
or duplications in a subset of 40 samples with
MPM and family history with sufficient DNA of
adequate quality, using the SALSA multiplex
ligation-dependent probe amplification kit ME024
9p21 CDKN2A/2B (MRC Holland BV, Amsterdam,
The Netherlands).42 The type of CDKN2A (exons 1a,
2, and 3), ARF (exon1b), CDK4 (exon 2), or MITF
mutation was recorded for each mutation-positive
patient. For novel variants, prediction of deleterious
effects on protein was performed by bioinformatic
criteria (tools for prediction of pathological muta-
tions: SIFT, Polyphen, pMut, SpliceView). When no
conclusive evidence of pathogenicity was obtained,
variants were classified as unknown significance and
excluded from the overall mutation rate calculation.
Statistical analyses
Statistical correlation between CDKN2A muta-
tions and clinical or pathological variables was
performed by x2 tests. Comparisons between
categorical variables were performed with x2 tests
and Fisher corrections where required. All analyses
were 2-tailed and P values of less than .05 were
considered statistically significant. Results are
reported as odds ratio and 95% confidence intervals.
RESULTS
A total of 112 of 587 (19%) patients with MPM and
26 of 587 (4.4%) with SPM harbored CDKN2A
mutations, regardless of family history (Table I). No
genomic alterations were detected by multiplex
ligation-dependent probe amplification in a
selection of 40 of 180 CDKN2A mutation-negative
MPM samples with a higher risk of being carriers of
genetic alterations (familial cases or MPM cases with
$3 melanomas), confirming previously described
results.42 Only 1 patient with SPM showed a
CDK4 mutation (c.70C[T, p.R24C)11 (Table II). No
mutation was found among control subjects. The
most common mutation was the founder G101W,
detected in 56% of the cases (Fig 1). The second
most frequent mutation was E27X followed by P48T
and R24P (7% and 5%, respectively), described as
founder or recurrent mutations.15,17,22,40,43 Novel
variants were observed, ie, S56R and F90S and
Table II. Cyclin-dependent kinase inhibitor 2A/
cyclin-dependent kinase 4 mutations in multiple
and single primary melanoma
MPM SPM CDKN2A Ink4 p16/p14 AA change
62 16 c.301G[T p.G101W/p.R115L
7 - c.142C[A p.P48T
6 1 c.71G[C p.R24P
4 5 c.79G[T p.E27X
3 - c.301G[C p.G101R/p.R115P
3 - c.339G[T p.A127S
2 - c.379G[C p.L113L/p.P114S
2 - c.251A[T p.D84V
2 - c.68G[A p.G23D
2 - c.66_67GG[AA p.G23S
2 - c.194T[C p.L65P
1 - c.202_203GC[TT p.A68L/p.R82L
1 - c.263A[G p.E88G
1 - c.67G[C p.G23R
1 - c.449G[T p.G150V
1 1 c.294C[T p.H98H/p.P113S
1 - c.149A[G p.Q50R
1 - c.148C[T p.Q50X
1 - c.172C[T p.R58X
1 - c.296G[C p.R99P
1 - c.167G[T p.S56I/p.Q70H
1 - c.168 C[A* p.S56R/p.R71S*
1 - c.229A[G p.T77A/p.H91R
1 - c.280_282insAG
1 - c.-25C[T & c.-180G[A
1 - c.-34G[T
1 - c.58delG c.58delG
- 1 c.269T[C* p.F90S*
- 1 c.281T[C p.L94P
1y 2y c.150137G[Cy
1 - c.151-18T[C &
c.151-13T[C*y
CDKN2A (exon 1b)
1 - g.19311 G[A
1y -y c.193154C[T*y
- CDK4 CDK4 AA change
- 1 c.70C[T R24C
CDK, Cyclin-dependent kinase; CDKN2A, cyclin-dependent kinase
inhibitor 2A; MPM, multiple primary melanoma; SPM, single
primary melanoma.
*Novel germline variants.
yVariants with unknown significance.
Table I. Cyclin-dependent kinase inhibitor 2A
mutation rates in multiple and single primary
melanoma by family history
Mutation rates
by family history
All Familial Sporadic
MPM SPM MPM SPM MPM SPM
Mutation carriers 112 26 64 15 48 11
WT 475 561 80 46 395 515
TOT 587 587 144 61 443 526
Mutation carriers, % 19 4.4 44.4 24.6 10.8 2.1
A comparison of cyclin-dependent kinase inhibitor 2A mutation
rates between MPM and SPM: all together; only familial cases; only
sporadic cases.
MPM, Multiple primary melanoma; SPM, single primary melanoma;
TOT, total; WT, wild type.
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CDKN2A and c.193154C[T in p14arf (Table II). The
S56R and F905 variants we found in the
coding regions were classified as pathogenetic based
on public in silico prediction tools and on their
absence in population controls. The c.280_282insAG
determines a stop codon downstream. No conclu-
sions could be drawn for the CDKN2A c.151-18T[C
& c.151-13T[C and the p14arf c.193154C[T as
these variants were predicted to have no effect on
messenger RNA processing using Splice View
prediction tool, but were not found in controls. As
for the CDKN2A c.150137G[C, there is no
conclusive evidence regarding pathogenicity, even
if a causal role cannot be excluded because of its
absence in the control populations and the alteration
of CDKN2A isoform 3.44 The other mutations were
described with evidence of pathogenicity.45-48
The highest mutation rate in MPM cases was
found in the northern regions of Italy, particularly
in Liguria and Lombardy, followed by Veneto (35%,
24%, and 12%, respectively), whereas the percentage
decreased in central regions, although remaining
near 10% (Fig 2). When family history was taken into
account, we observed that the prevalence of
CDKN2A mutations in patients with MPM was as
high as 44.4%. Despite regional differences, a
considerable proportion of the patients with MPM
without family history (10.8%) harbored CDKN2A
mutations (Table I). The frequency of mutations
increased significantly as the number of melanomas
increased, going from 14.6% in patients with 2
melanomas to 29.6% in those with 3 or more
melanomas (P\ .0001) (Table III). In familial MPM
cases the mutation rate varied from 36.6% in patients
with 2melanomas to 58.8% in patients with 3 or more
melanomas (P = .0139), whereas in sporadic MPM
cases the difference in mutation rate varied from
8.2% in patients with 2 melanomas to 17.6% in
patients with 3 or more melanomas (P = .0062).Because in situ melanomas accounted for about
22% of our MPM cohort, we wondered whether
including these lesions could have modified or
biased the observed mutation rates. We performed
the analyses by excluding cases with in situ mela-
nomas to quantify their influence on the total muta-
tion rate. We did not find any significant differences
in the mutation rate between the categories we
studied, or among all MPM (P = .5594) or familial
(P = .7249) or sporadic (P = .593) MPM, whereas
Fig 2. Cyclin-dependent kinase inhibitor 2A (CDKN2A)
mutation regional distribution. Percentage of germline
CDKN2A mutations in patients with multiple primary
melanoma (MPM) and number of patients with MPM is
indicated in parentheses for each region. Dots show the
geographic location of participating centers. *Patients from
Naples and Sassari referred to the center of Sassari for
testing.
Table III. Cyclin-dependent kinase inhibitor 2A
mutation rates in multiple primary melanoma and
number of melanomas in correlation with the
number of melanoma occurrences in a single
patient
MPM
All Familial Sporadic
2 $3 2 $3 2 $3
Mutation carriers 60 52 34 30 26 22
WT 351 124 59 21 292 103
TOT 411 176 93 51 318 125
Mutation carriers, % 14.6 29.6 36.6 58.8 8.2 17.6
A comparison of cyclin-dependent kinase inhibitor 2A mutation
rates among MPM by number of melanomas: all together; only
familial cases; only sporadic cases.
MPM, Multiple primary melanoma; TOT, total; WT, wild type.
Fig 1. Cyclin-dependent kinase inhibitor 2A mutation
distribution. Frequency of mutation-positive patients is
indicated after each mutation name.
Table IV. Association of cyclin-dependent kinase
inhibitor 2A mutations with pancreatic cancer in
patients with single and multiple primary
melanoma
Pancreatic
cancer and
CDKN2A
mutations
SPM MPM
Pancreatic
cancer
No pancreatic
cancer
Pancreatic
cancer
No
pancreatic
cancer
Mutation
carriers
3 9 11 101
WT 11 378 21 441
TOT 14 387 37 537
OR (95% CI) 8.84 (2.18-35.85) 2.29 (1.06-4.89)
P .0023 .0331
Correlation between the presence of pancreatic cancer in a patient
and/or in the family and the presence of cyclin-dependent kinase
inhibitor 2A mutations in SPM and MPM cases.
CI, Confidence interval;MPM, multiple primary melanoma;OR, odds
ratio; SPM, single primary melanoma; TOT, total; WT, wild type.
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have implied the loss of a significant proportion of
mutation carriers.
The overall CDKN2A/CDK4 mutation rate in
SPM was 4.4% (26/587) vs 19% of MPM cases and
although 24.6% of familial SPM were CDKN2A1
(15/61), only 2.1% of sporadic SPM were mutation
carriers (11/526) versus 8.2% of patients withsporadic MPM and only 2 melanomas (P \ .0001)
(Table I). The sporadic SPM mutation carriers
showed a slightly significant association with
the presence of pancreatic cancer, both in the
patient and among first- or second-degree relatives
(P = .0023) (Table IV). The cases with an insufficient
degree of confirmation of cancer family history were
excluded. The same comparison among patients
with MPMwith or without pancreatic cancer resulted
in a highly significant difference (P = .0002).
The median age at diagnosis of patients with MPM
was 45 years (range 15-91) and it was significantly
different (P\.0001) in CDKN2A1 patients (39 years
in familial cases vs 38 years in sporadic cases,
P = .7280) compared with patients with no mutations
(44 years in familial cases vs 48 years in sporadic
cases, P = .0443). The median age at diagnosis of
patients with SPM was 49 years (range 15-89). The
Table V. Prevalence of the microphthalmia-associated transcription factor E318K mutation in multiple and
single primary melanoma on a national basis
MITF E318K
All Familial Sporadic
MPM SPM MPM SPM MPM SPM
Mutation carriers 12 3 1 0 11 3
WT 366 411 69 39 297 372
TOT 378 414 70 39 308 375
Mutation carriers, % 3.2 0.7 1.4 0 3.6 0.8
OR (95% CI) 4.49 (1.26-16.04) 1.71 (0.08-42.86) 4.59 (1.27-16.61)
P .0207 .7457 .021
A comparison of MITF mutation rates between MPM and SPM: all together; only familial cases; and only sporadic cases.
CI, Confidence interval; MITF, microphthalmia-associated transcription factor; MPM, multiple primary melanoma; OR, odds ratio; SPM, single
primary melanoma; TOT, total; WT, wild type.
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cases was not statistically significant (37 years in
familial cases vs 46 years in sporadic cases,
P = .0950). Even the difference between sporadic
mutation carriers and wild type SPM was not
significant (46 vs 48 years, P = .8038), and the age
at diagnosis of patients with sporadic wild type SPM
and MPM was the same.
We also evaluated the prevalence of MITF
mutations in patients for whom MITF analysis had
been performed after ruling out CDKN2A/CDK4
mutations. Two cases (1 sporadic MPM and 1 familial
SPM) carrying the mutation in both MITF and
CDKN2A were also excluded from the analysis.
The MITF E318K mutation rate in CDKN2A/CDK4e
MPM was 3.2%, whereas in SPM cases it was 0.7%. A
comparison between MPM cases vs SPM cases
showed a stronger association of MITF with
multiple events in both familial and sporadic cases
(Table V).
DISCUSSION
This multicenter study confirms that, despite
regional differences caused by the presence of
founder mutations, the development of MPM, even
in the absence of melanoma family history, can be
considered a single criterion for referral to genetic
counseling on a national basis. The percentage of
sporadic MPM mutation carriers is about 10%, even
considering areas where founder mutations are not
prevalent and consequently CDKN2Amutation rates
are lower. When family history is positive, the
presence of MPM cases is confirmed as a strong
mutation-predictive parameter. Although the results
of SPM analysis confirm that familial cases show a
high percentage of mutation carriers, the rate is
nonetheless below 5% when family history is not
present.
We decided to combine invasive and in situ
melanomas in the same analyses. In situ melanomaswere often not considered for genetic studies or risk
assessment, even if patients with in situ melanomas
have a higher risk of developing invasive
melanoma.49 A northern European study proved
that in situ melanomas confer a familial risk equal
to that of invasive melanomas.50 In situ melanomas
accounted for about 22% of our MPM cohort and our
analysis showed that the extent to which in situ
melanomas and invasive melanomas contribute to
the mutation rate is comparable.
Currently, SIGU recommendations do not include
the presence of pancreatic cancer in the proband or
in relatives among the criteria for access to genetic
counseling given that data on pancreatic cancer risk
in melanoma families are available only for the
Italian region Liguria and that there is no national
agreement for a protocol that could be offered to
individuals at high risk of pancreatic cancer.16,19,20
Our results support the validity of the internationally
proposed criteria for genetic referral for low
melanoma incidence areas, including pancreatic
cancer as the second cancer event other than
melanoma.13 Because further refinement of the
criteria for identifying patients at high risk for
pancreatic cancer based on their genetic background
is still needed, as is a nationally approved
surveillance protocol, we suggest the association
between CDKN2A mutations and pancreatic cancer
should be managed carefully by the referring
clinicians and genetic counselors.
Some Italian genetics centers currently analyze
MITF in melanoma cases for research purposes. Our
analysis shows that MITF is responsible for sporadic
MPM susceptibility in about 3% of cases. Because of
the correlation with multiple melanoma events, we
suggest that diagnostic testing in MPM cases could be
improved by molecular analysis of MITF.
Although younger age of onset is a feature of
CDKN2A mutations, in the absence of family history
the selection of patients based on young age at
J AM ACAD DERMATOL
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sufficiently high likelihood of finding a mutation to
warrant referral.13 Furthermore, we have observed
an alarming trend toward lower age at diagnosis in
CDKN2Ae subjects, which is currently approaching
the age at diagnosis of mutation carriers.
A limit of the study was that it is not population
based and not all Italian regions were represented.
However, most of the participating centers perform
genetic counseling and dermatologic examinations
for patients coming from other areas. Rare mutations
in novel melanoma susceptibility genes, including a
founder mutation in POT1 in families from the Italian
region Emilia-Romagna, have been identified31-36
but were not tested. However, such mutations occur
in less than 10% of melanoma families with a yet
unknown genetic prevalence in the studied
populations. In general, the possibility that
founder effects influence the CDKN2A mutation
prevalence in our population should be carefully
considered.41,51-53 Founder mutations are common
among hereditary melanoma cases in some Italian
regions, but this high prevalence in a defined area
can not imply a national predictive value.15,17,43,51,54
In the view of the implementation of next generation
sequencing methods, eg, gene panels, in clinical
genetic testing, further population studies are
needed to establish the mutation prevalence and
penetrance of these genes in different countries.
In conclusion,our study shows that, despite regional
differences, Italian patients presenting with only 2
melanomas, even in situ, warrant genetic counseling
even in the absence of positive family history.
We thank Frigerio Simona and Peissel Bernard
(Fondazione IRCCS Istituto Nazionale Tumori, Milan,
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